Literature DB >> 31887437

Skeletal dynamics of Down syndrome: A developing perspective.

Jonathan M LaCombe1, Randall J Roper2.   

Abstract

Individuals with Down syndrome (DS) display distinctive skeletal morphology compared to the general population, but disparate descriptions, methodologies, analyses, and populations sampled have led to diverging conclusions about this unique skeletal phenotype. As individuals with DS are living longer, they may be at a higher risk of aging disorders such as osteoporosis and increased fracture risk. Sexual dimorphism has been suggested between males and females with DS in which males, not females, experience an earlier decline in bone mineral density (BMD). Unfortunately, studies focusing on skeletal health related to Trisomy 21 (Ts21) are few in number and often too underpowered to answer questions about skeletal development, resultant osteoporosis, and sexual dimorphism, especially in stages of bone accrual. Further confounding the field are the varied methods of bone imaging, analysis, and data interpretation. This review takes a critical look at the current knowledge of DS skeletal phenotypes, both from human and mouse studies, and presents knowledge gaps that need to be addressed, differences in research methodologies and analyses that affect the interpretation of results, and proposes guidelines for overcoming obstacles to understand skeletal traits associated with DS. By examining our current knowledge of bone in individuals with Ts21, a trajectory for future studies may be established to provide meaningful solutions for understanding the development of and improving skeletal structures in individuals with and without DS.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Developmental modeling; Down syndrome; Genetic animal models; Osteoporosis; Skeletal abnormalities; Trisomy 21

Year:  2019        PMID: 31887437      PMCID: PMC7044033          DOI: 10.1016/j.bone.2019.115215

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  105 in total

1.  Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy.

Authors:  D A Nyberg; V L Souter; A El-Bastawissi; S Young; F Luthhardt; D A Luthy
Journal:  J Ultrasound Med       Date:  2001-10       Impact factor: 2.153

2.  Fetal nose bone length: a marker for Down syndrome in the second trimester.

Authors:  Bryann Bromley; Ellice Lieberman; Thomas D Shipp; Beryl R Benacerraf
Journal:  J Ultrasound Med       Date:  2002-12       Impact factor: 2.153

3.  Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.

Authors:  Joshua D Blazek; Anna Gaddy; Rachel Meyer; Randall J Roper; Jiliang Li
Journal:  Bone       Date:  2010-09-24       Impact factor: 4.398

4.  Femur and humerus length in trisomy 21 fetuses at 11-14 weeks of gestation.

Authors:  D Longo; D DeFigueiredo; S Cicero; C Sacchini; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2004-02       Impact factor: 7.299

5.  Clinical identification of feeding and swallowing disorders in 0-6 month old infants with Down syndrome.

Authors:  Maria A Stanley; Nicole Shepherd; Nichole Duvall; Sandra B Jenkinson; Hasnaa E Jalou; Deborah C Givan; Gregory H Steele; Charlene Davis; Marilyn J Bull; Donna U Watkins; Randall J Roper
Journal:  Am J Med Genet A       Date:  2018-12-27       Impact factor: 2.802

6.  Bone Mineral Density Distribution Curves in Spanish Adults With Down Syndrome.

Authors:  Ramón Costa; Alejandra Gullón; Rosa De Miguel; Diego Real de Asúa; Azucena Bautista; Clara García; Carmen Suarez; Santos Castañeda; Fernando Moldenhauer
Journal:  J Clin Densitom       Date:  2018-03-21       Impact factor: 2.617

7.  A mouse model for Down syndrome exhibits learning and behaviour deficits.

Authors:  R H Reeves; N G Irving; T H Moran; A Wohn; C Kitt; S S Sisodia; C Schmidt; R T Bronson; M T Davisson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

8.  Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.

Authors:  Elena Tsourdi; Polyzois Makras; Tilman D Rachner; Stergios Polyzos; Martina Rauner; Stylianos Mandanas; Lorenz C Hofbauer; Athanasios D Anastasilakis
Journal:  Bone       Date:  2018-10-04       Impact factor: 4.398

Review 9.  Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence.

Authors:  Armin Rashidi; John F DiPersio
Journal:  Ther Adv Hematol       Date:  2016-02

10.  People with mental retardation have an increased prevalence of osteoporosis: a population study.

Authors:  J Center; H Beange; A McElduff
Journal:  Am J Ment Retard       Date:  1998-07
View more
  8 in total

1.  Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).

Authors:  Kirby M Sherman; Diarra K Williams; Casey A Welsh; Alexis M Cooper; Alyssa Falck; Shannon Huggins; Rihana S Bokhari; Dana Gaddy; Kent D McKelvey; Lindsay A Dawson; Larry J Suva
Journal:  Bone       Date:  2022-06-15       Impact factor: 4.626

2.  Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.

Authors:  Laura E Hawley; Faith Prochaska; Megan Stringer; Charles R Goodlett; Randall J Roper
Journal:  Pharmacol Biochem Behav       Date:  2022-05-14       Impact factor: 3.697

Review 3.  Current Analysis of Skeletal Phenotypes in Down Syndrome.

Authors:  Jared R Thomas; Randall J Roper
Journal:  Curr Osteoporos Rep       Date:  2021-04-08       Impact factor: 5.163

4.  Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome.

Authors:  Jared R Thomas; Jonathan LaCombe; Rachel Long; Eva Lana-Elola; Sheona Watson-Scales; Joseph M Wallace; Elizabeth M C Fisher; Victor L J Tybulewicz; Randall J Roper
Journal:  Bone       Date:  2020-04-17       Impact factor: 4.398

5.  Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.

Authors:  Jared R Thomas; Kourtney Sloan; Kelsey Cave; Joseph M Wallace; Randall J Roper
Journal:  Genes (Basel)       Date:  2021-10-28       Impact factor: 4.141

6.  Comprehensive phenotypic analysis of the Dp1Tyb mouse strain reveals a broad range of Down syndrome-related phenotypes.

Authors:  Eva Lana-Elola; Heather Cater; Sheona Watson-Scales; Simon Greenaway; Jennifer Müller-Winkler; Dorota Gibbins; Mihaela Nemes; Amy Slender; Tertius Hough; Piia Keskivali-Bond; Cheryl L Scudamore; Eleanor Herbert; Gareth T Banks; Helene Mobbs; Tara Canonica; Justin Tosh; Suzanna Noy; Miriam Llorian; Patrick M Nolan; Julian L Griffin; Mark Good; Michelle Simon; Ann-Marie Mallon; Sara Wells; Elizabeth M C Fisher; Victor L J Tybulewicz
Journal:  Dis Model Mech       Date:  2021-10-15       Impact factor: 5.732

7.  Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Authors:  Raza Jamal; Jonathan LaCombe; Roshni Patel; Matthew Blackwell; Jared R Thomas; Kourtney Sloan; Joseph M Wallace; Randall J Roper
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.752

8.  Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.

Authors:  Sergi Llambrich; Rubèn González-Colom; Jens Wouters; Jorge Roldán; Sara Salassa; Kaat Wouters; Vicky Van Bulck; James Sharpe; Zsuzsanna Callaerts-Vegh; Greetje Vande Velde; Neus Martínez-Abadías
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.